Floatz logo

rtx001

Steatotic Liver Disease

Resolution Therapeutics LimitedCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

26 Active assets in the Steatotic Liver Disease cohort.

Asset / SponsorPhaseRating
Metformin
Leiden University Medical Center
Phase 4BBB
Alpha Tocopherol
Yuen Kah Hay
Phase 4BB
Dolutegravir
Fundacion SEIMC-GESIDA
Phase 4BB
Raltegravir
Helsinki University Central Hospital
Phase 4BB
Empagliflozin
Seoul National University Bundang Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

rtx001 is also rated in:

chronic liver failureDormant
CCC
Indicative ·
48 / 100
View asset →
cirrhosis of liverDormant
CC
Indicative ·
47 / 100
View asset →
liver disorderDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →